Document Detail


Relationship between biliary and serum bile acids and response to ursodeoxycholic acid in patients with primary biliary cirrhosis.
MedLine Citation:
PMID:  9732932     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: Ursodeoxycholic acid (UDCA) improves liver biochemistries and enriches the bile with UDCA in patients with primary biliary cirrhosis. The aim of this study was to determine whether the degree of enrichment of bile correlated with that of serum and whether either of these measures correlated with improvement in measures of liver disease. METHODS: In a randomized study, biliary and serum bile acid analyses were performed at entry and after 2 yr of UDCA or placebo. RESULTS: The percentage of ursodeoxycholic acid in bile increased by 42% in the UDCA group (n = 61) compared with 8% in the placebo group (n = 57) (p < 0.0001). Measurement of serum bile acids in 32 patients (18 ursodeoxycholic acid, 14 placebo) indicated that at 2 yr, ursodeoxycholic acid comprised 65% of serum bile acids in the treated group and 7% in the placebo group. Agreement between bile and serum was fair (r = 0.75, p < or = 0.00002) because in some patients, plasma but not biliary bile acids were enriched with UDCA. Changes in biliary ursodeoxycholic acid correlated significantly but weakly with the changes in serum alkaline phosphatase, AST, bilirubin, and in Mayo risk score. Correlations between changes in serum bile acid composition and biochemical measures of disease activity were even weaker. CONCLUSION: The measurement of biliary bile acids is superior to that of serum bile acids for assessing the compliance and changes in the circulating bile acids in patients receiving ursodeoxycholic acid for the treatment of primary biliary cirrhosis. Furthermore, measures to further increase the proportion of ursodeoxycholic acid in circulating bile acids should be explored.
Authors:
K D Lindor; M A Lacerda; R A Jorgensen; C K DeSotel; A K Batta; G Salen; E R Dickson; S S Rossi; A F Hofmann
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  The American journal of gastroenterology     Volume:  93     ISSN:  0002-9270     ISO Abbreviation:  Am. J. Gastroenterol.     Publication Date:  1998 Sep 
Date Detail:
Created Date:  1998-09-15     Completed Date:  1998-09-15     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  0421030     Medline TA:  Am J Gastroenterol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1498-504     Citation Subset:  IM    
Affiliation:
Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Bile / metabolism*
Bile Acids and Salts
Chenodeoxycholic Acid / metabolism
Cholagogues and Choleretics / blood,  metabolism*,  therapeutic use
Cholic Acids / metabolism
Double-Blind Method
Humans
Liver Cirrhosis, Biliary / metabolism*
Patient Compliance
Ursodeoxycholic Acid / blood,  metabolism*,  therapeutic use
Grant Support
ID/Acronym/Agency:
DK21506/DK/NIDDK NIH HHS
Chemical
Reg. No./Substance:
0/Bile Acids and Salts; 0/Cholagogues and Choleretics; 0/Cholic Acids; 128-13-2/Ursodeoxycholic Acid; 474-25-9/Chenodeoxycholic Acid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Outcome states of colorectal cancer: identification and description using patient focus groups.
Next Document:  Serum apolipoprotein(a) concentrations and Apo(a) phenotypes in patients with liver cirrhosis.